Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant humanized anti-PD-1 monoclonal antibody

· Shanghai Junshi Bioscience Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant humanized anti-PD-1 monoclonal antibody, covering 2020-09-30 to 2020-09-30. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma [Phase 2]

See pricing